Regeneus Ltd. (AU:CMB)
ASX:CMB
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)3.93K
Market Cap
AU$13.12M
Enterprise ValueAU$11.34M
Total Cash (Recent Filing)AU$166.41K
Total Debt (Recent Filing)AU$482.71K
Price to Earnings (P/E)―
Beta-3.47
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding27,331,919
10 Day Avg. Volume7,693
30 Day Avg. Volume3,926
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.09
Price to Sales (P/S)5.73
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA material top-line rebound after a low base indicates improving commercial traction and validates demand for the company’s R&D outputs. Sustained revenue growth would improve operating leverage, support larger clinical programs or partnerships, and reduce reliance on capital raises over the next 2–6 months.
Strong Gross MarginA high gross margin suggests favorable unit economics for the company’s cell-based products or services. If revenue scales, this margin profile supports sustainable profitability over time and provides room to absorb fixed R&D and G&A costs, improving long-term margin recovery prospects.
Moderate LeverageRelatively low debt levels mean the company is not heavily reliant on borrowing to fund operations, reducing near-term refinancing pressure. This provides balance-sheet flexibility to execute clinical programs or negotiate partnerships without immediate debt overhang for several months ahead.
Bears Say
High Cash BurnSignificant negative operating and free cash flow are structural constraints that will likely require new financing or spending cuts. Persistent cash burn materially increases funding and dilution risk, limits strategic optionality, and could force deprioritisation of programs if additional capital is not secured within months.
Ongoing Net LossesContinued multi‑year net losses demonstrate that the current revenue base does not yet support the company’s cost structure. Persistent unprofitability weakens return metrics, heightens dependence on external funding, and reduces ability to self‑fund development milestones over a medium-term horizon.
Equity Erosion & Prior StressA history of negative equity and recent equity erosion signal prior solvency stress and raise the prospect of future dilution. If losses continue, shareholders face increased dilution risk and the company’s capital structure may constrain its ability to raise non‑dilutive partner funding over the next several months.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.19 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$13.12M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 152 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 27,331,919 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth AU$2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.22%
12-Months-Change
Fundamentals
Return on Equity
-218.76%
Trailing 12-Months
Asset Growth
-5.07%
Trailing 12-Months
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---